Highlights from: The 2009 annual meeting of the american society of clinical oncology May 29-June 2, 2009 Orlando, Fl

Clinical Breast Cancer

Volumn 9, Issue 3, 2009, Pages 140-144

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; BSI 201; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PLATINUM; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANEMIA; BLEEDING; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DNA DAMAGE; DNA REPAIR; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; MEDICAL SOCIETY; METASTASIS; MUTATION; NAUSEA; NEUTROPENIA; ONCOGENE; ONCOLOGY; PROTEINURIA; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 73549098929     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.023     Document Type: Conference Paper

References (20)

1. Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8:193-204.
2. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.
3. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
4. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC) : results of a randomized phase II trial. J Clin Oncol 2009;27(18 suppl) :793s (Abstract 3).
5. Tan AR, Swain SM. Therapeutic strategies for triplenegative breast cancer. Cancer J 2008;14:343-51.
6. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009;27(18 suppl) :803s (Abstract CRA501).
7. ClinicalTrials.gov [Web site]. A phase 2 study of standard chemotherapy plus BSI-201 (a PARP inhibitor) in the neoadjuvant treatment of triple negative breast cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00813956. Accessed: June 10, 2009.
8. ClinicalTrials.gov [Web site]. Phase II, open label, non-randomized study of AZD2281 in the treatment of patients with known BRCA or recurrent high grade serous/undifferentiated tubo-ovarian carcinoma and in known BRCA or triple negative breast cancer to determine response rate and correlative markers of response. Available at: http://clinicaltrials.gov/ct2/show/NCT00679783. Accessed: June 10, 2009.
9. ClinicalTrials.gov [Web site]. Phase I/II randomised, double-blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic triple negative breast cancer. Available at: http://clinicaltrials.gov/ct2/show/ NCT00707707. Accessed: June 10, 2009.
10. ClinicalTrials.gov [Web site]. A phase I/II, open label, multi-centre study of AZD2281 administered orally in combination with cisplatin, to assess the safety and tolerability in patients with advanced solid tumours, and to assess efficacy in the neoadjuvant setting for patients with triple negative breast cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00782574. Accessed: June 10, 2009.
11. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9.
12. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
13. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (MBC) : AVADO. J Clin Oncol 2008;26(suppl) :43s (Abstract LBA1011).
14. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009;27(18 suppl) :42s (Abstract 1005).
15. ClinicalTrials.gov [Web site]. A phase III, multicenter, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer. Available at: http://clinicaltrials.gov/ct2/show/ NCT00281697. Accessed: June 11, 2009.
16. Perez EA, Romond E, Suman V. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007;25(suppl) :6s (Abstract 512).
17. Smith I, Procter M, Gelber RD, et al. 2-year followup of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
18. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res Treat 2006;100: Abstract 52.
19. Miller D, Jenkins R, Lingle W, et al. Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization: Data from NCCTG N9831 Intergroup Adjuvant Trial. J Clin Oncol 2004;22(suppl) :7 (Abstract 568).
20. Sukov W, Miller D, Dueck A, et al. Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial. J Clin Oncol 2009;27(suppl) : (Abstract 520).